Lu, Yi-Tsung Plets, Melissa Morrison, Gareth Cunha, Alexander T Cen, Steven Y Rhie, Suhn K Siegmund, Kimberly D Daneshmand, Siamak Quinn, David I Meeks, Joshua J
...
Published in
European urology oncology
Neoadjuvant chemotherapy (NAC) is the standard of care in muscle-invasive bladder cancer (MIBC). However, treatment is intense, and the overall benefit is small, necessitating effective biomarkers to identify patients who will benefit most. To characterize cell-free DNA (cfDNA) methylation in patients receiving NAC in SWOG S1314, a prospective coop...
Frost, Nikolaj Bleckmann, Annalen Griesinger, Frank Grohé, Christian Janning, Melanie Kollmeier, Jens Reinmuth, Niels Sebastian, Martin Thomas, Michael Reck, Martin
...
Published in
Clinical lung cancer
Pemetrexed-based immunochemotherapy represents an established standard of care as first line treatment for non-oncogenic driven metastatic non-small cell lung adenocarcinoma (NSCLC/ADC). However, retrospective analyses revealed better outcomes for pemetrexed-free regimens compared to pemetrexed-containing regimens in patients with thyroid transcrip...
Lederer, Christoph Mayer, Katharina Somogyi, Vivien Kriegsmann, Katharina Kriegsmann, Mark Buschulte, Katharina Polke, Markus Findeisen, Peter Herth, Felix Kreuter, Michael
...
Published in
Respiration
Background: As fibrosing interstitial lung diseases (fILDs) are associated with high mortality, monitoring of disease activity under treatment is highly relevant. Krebs von den Lungen-6 (KL-6) is associated with the presence and severity of different fILDs, mainly in Asian patient populations. Objectives: Our aim was to evaluate KL-6 as a predictiv...
Sallinger, Katja Gruber, Michael Müller, Christin-Therese Bonstingl, Lilli Pritz, Elisabeth Pankratz, Karin Gerger, Armin Smolle, Maria Anna Aigelsreiter, Ariane Surova, Olga
...
Published in
Journal of translational medicine
Opting for or against the administration of adjuvant chemotherapy in therapeutic management of stage II colon cancer remains challenging. Several studies report few survival benefits for patients treated with adjuvant therapy and additionally revealing potential side effects of overtreatment, including unnecessary exposure to chemotherapy-induced t...
Lodi, Massimo
Les cancers du sein HER2+ sont caractérisés par l’amplification et la surexpression d’HER2. Ce sous-groupe a un pronostic défavorable et nécessite un traitement spécifique ciblant HER2. Le laboratoire dans lequel j’ai réalisé ma thèse a identifié le gène STARD3 (StAR-related lipid transfer Domain protein 3), co-amplifié et co-exprimé avec HER2. Les...
Gu, Yun Zhang, Puran Wang, Jieti Lin, Chao Liu, Hao Li, He He, Hongyong Li, Ruochen Zhang, Heng Zhang, Weijuan
...
Published in
Cancer immunology, immunotherapy : CII
AT-rich interaction domain 1A (ARID1A) encodes a vital component of switch/sucrose non-fermentable chromatin-remodeling complex. Given its association with genomic instability, we conducted this study to determine whether ARID1A mutation status had an impact on therapeutic responsiveness in gastric cancer (GC), especially combinatory chemo-immunoth...
Pavord, Ian D Deniz, Yamo Corren, Jonathan Casale, Thomas B FitzGerald, J Mark Izuhara, Kenji Daizadeh, Nadia Ortiz, Benjamin Johnson, Robert R Harel, Sivan
...
Published in
The journal of allergy and clinical immunology. In practice
FeNO may have a role as both a prognostic and predictive biomarker in combination with eosinophils for assessing responsiveness to some biological therapies. We evaluated the value of baseline FeNO, adjusted for baseline blood eosinophil levels and other clinical characteristics, as an independent predictor of treatment response to dupilumab in pat...
Altena, Renske Tzortzakakis, Antonios Buren, Siri Af Tran, Thuy A. Frejd, Fredrik Y. Bergh, Jonas Axelsson, Rimma
BackgroundExpanding therapeutic possibilities have improved disease-related prospects for breast cancer patients. Pathological analysis on a tumor biopsy is the current reference standard biomarker used to select for treatment with targeted anticancer drugs. This method has, however, several limitations, related to intra- and intertumoral as well a...
Nose, Yohei Saito, Takuro Yamamoto, Kei Yamashita, Kotaro Tanaka, Koji Yamamoto, Kazuyoshi Makino, Tomoki Takahashi, Tsuyoshi Kawashima, Atsunari Haruna, Miya
...
Published in
Cancer immunology, immunotherapy : CII
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Since clinical benefits are limited to a subset of patients, we aimed to identify peripheral blood biomarkers that predict the efficacy of the anti-programmed cell death protein 1 (PD-1) antibody (nivolumab) in patients with gastric cancer. We collected peripheral blood sampl...
He, Meng-Ye Yan, Fei-Fei Cen, Kai-Li Shen, Peng
Published in
World journal of clinical cases
Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary hepatic malignancy worldwide. However, currently available systemic therapies are of limited effectiveness, and the median overall survival of patients treated with first-line standard chemotherapy is less than one year. Immune checkpoint inhibitors have been used to treat sol...
